Calm clarity without the fog
Nasal · 503A Compounding
Educational content. This page describes Selank for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.
Selank raised brain-derived neurotrophic factor levels in the hippocampus and prefrontal cortex of rats, a neurotrophic signal tied to synaptic plasticity and neuroprotection.[10]
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is built on the naturally occurring immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tail at the C-terminus to slow enzymatic breakdown and lengthen its activity.
In Russia, Selank is registered as a prescription anxiolytic and is administered as nasal drops. It is not approved by the FDA and has not been evaluated in large Western-standard randomized trials, so most of its clinical record comes from Russian research institutions. The interest in Selank stems from a profile rarely seen in conventional anxiolytics: anxiety relief that, in the available studies, did not bring sedation, amnesia, or dependence.
Because it descends from tuftsin, Selank also carries immunomodulatory activity, and a meaningful share of its published literature examines effects on inflammatory signaling rather than mood alone.
Selank appears to act through several neurotransmitter systems at once rather than a single receptor. On the GABAergic side, cell and animal studies show it alters expression of genes encoding GABA-A receptor subunits, which can raise inhibitory tone without the direct receptor agonism that defines benzodiazepines. That indirect route is the leading explanation for why, in comparative studies, it produced anxiolytic effects without the sedation and dependence associated with that drug class.
A second, well-characterized mechanism runs through the endogenous opioid system. Selank slows the breakdown of leu-enkephalin in human serum, and in the clinical study of anxiety patients the lengthening of enkephalin half-life tracked with symptom improvement. In animal work, its modulation of dopamine-driven behavior was reversed by the opioid blocker naloxone, further implicating enkephalin signaling.
Selank also influences monoamines and neurotrophic factors. In mice it shifted serotonin, dopamine, and noradrenaline metabolism in a strain-dependent way, and in rats it increased hippocampal and prefrontal BDNF. These actions help explain why a compound used for anxiety can also support learning and memory, a combination uncommon among sedative anxiolytics.
Calm clarity without the fog
Selank works through several systems at once: it adjusts GABA-A receptor subunit gene expression to raise inhibitory tone without direct benzodiazepine-site binding, slows degradation of enkephalins to engage the endogenous opioid system, shifts serotonin and dopamine metabolism, and raises BDNF in the hippocampus and prefrontal cortex. Together these actions produce anxiolytic effects without sedation alongside support for learning and memory in the available preclinical and Russian clinical data.
Selank's anxiolytic effect was comparable to the benzodiazepine medazepam but added antiasthenic and psychostimulant effects. Treatment lengthened the half-life of leu-enkephalin in serum, and that increase correlated with anxiety improvement, mainly in the GAD group.
Zozulia AA, Neznamov GG, Siuniakov TS, et al. · Zh Nevrol Psikhiatr Im S S Korsakova, 108(4):38-48 (2008) · PubMed
Selank produced pronounced anxiolytic and mild nootropic effects with good tolerability. The anxiolytic effect persisted for about a week after the last dose, and quality-of-life scores improved.
Medvedev VE, Tereshchenko ON, Israelian AIu, et al. · Zh Nevrol Psikhiatr Im S S Korsakova, 114(7):17-22 (2014) · PubMed
Adding Selank to phenazepam reduced benzodiazepine side effects including memory impairment, sedation, and asthenia during treatment and after withdrawal, improving overall quality of life.
Medvedev VE, Tereshchenko ON, Kost NV, et al. · Zh Nevrol Psikhiatr Im S S Korsakova, 115(6):33-40 (2015) · PubMed
A functional connectomic analysis found that Selank altered functional connectivity in limbic and cortical networks, offering neuroimaging-level support for its central effects.
Panikratova YR, Lebedeva IS, Sokolov OY, et al. · Dokl Biol Sci, 490(1):9-11 (2020) · PubMed
start low, go slow
Intranasal
Subcutaneous Injection
Intranasal: The route used in Russian clinical practice; absorbed through the nasal mucosa with central uptake.
Subcutaneous Injection: An alternative seen in some compounded protocols; the nasal route has the larger evidence base.
Dosing is determined by a licensed provider based on your goals, history, and response. The figures above describe ranges reported in the research literature, not a prescription.
Selank is typically run in cycles of two to three weeks followed by a comparable break, the pattern used in Russian clinical protocols.
Intranasal administration is the most studied route and provides absorption through the nasal mucosa with central nervous system uptake. Effects on anxiety are often noticed early in a cycle, with cognitive benefits accumulating over the first week.
In comparative trials against benzodiazepines, Selank showed an anxiolytic effect with fewer side effects and no reported sedation, dependence, tolerance, or withdrawal, which is the central reason it has drawn research interest.
Long-term safety data from large Western-standard randomized controlled trials does not exist. Most published clinical evidence comes from Russian research institutions, and Selank is not FDA-approved for any use in the United States.
The FDA has flagged immunogenicity as a concern for Selank as a compounded substance, reflecting the general uncertainty around peptide impurities and immune responses rather than a finding from a specific adverse-event report.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Selank | Anxiolytic & Nootropic | Intranasal | 14-21 days | Benzodiazepine-comparable anxiety relief in Russian trials without the sedation, cognitive dulling, or dependence |
| Semax | Nootropic & Neuroprotective | Intranasal | 10–21 days | Directly upregulates BDNF (the brain's primary growth factor for learning and memory) without hormonal side effects |
| Dihexa | Cognitive Enhancement | Oral, Injection | 30–60 days | Orally bioavailable angiotensin IV analog designed to drive synaptogenesis through the HGF/c-Met pathway |
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
Originally placed in Category 2 in September 2023. Removed from the formal Category 2 list in September 2024 because 'FDA received additional information from the nominator indicating that they intended to nominate a different bulk drug substance.' Still listed on the FDA safety-risks page with immunogenicity concerns. Effectively remains ineligible for 503A compounding. Not among the 12 peptides HHS withdrew from Category 2 in April 2026.
Removed from formal Category 2 after FDA received additional information indicating the nominator intended to nominate a different substance
Placed in 503A Category 2 as Selank acetate (TP-7)
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Zozulia AA, Neznamov GG, Siuniakov TS, et al. “Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia.” Zh Nevrol Psikhiatr Im S S Korsakova, 108(4):38-48 (2008)
Medvedev VE, Tereshchenko ON, Israelian AIu, et al. “A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders.” Zh Nevrol Psikhiatr Im S S Korsakova, 114(7):17-22 (2014)
Narkevich VB, Kudrin VS, Klodt PM, et al. “Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study.” Eksp Klin Farmakol, 71(5):8-12 (2008)
Looking into Selank? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA 7-residue ACTH(4-7) analog studied for memory, focus, and nerve regeneration.
Russian-origin neuropeptide approved in Russia for stroke recovery; evidence base is largely outside the Western literature.
An orally active angiotensin IV-derived peptidomimetic studied for synaptogenesis and cognition.
No published human clinical trials; the evidence base remains preclinical and animal-model driven.
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering Selank.